The mission of TregTherapeutics, Inc is to provide resources to expedite the pre-clinical development, and ultimately, the availability of next-generation therapeutics in the treatment of autoimmune disease.
The technology covered under the company’s license agreement is multifaceted with several layers of complexity. First, there are two separate technologies, specified as “Vaccine Therapy” and “Adaptive Cell Therapy,” and each of these technologies has potential application to a range of autoimmune disease states and urgent target markets. Management has decided that its primary priority is to develop the Vaccine Therapy first. The vaccine approach defined by our platform technology is applicable to dozens of autoimmune diseases, each having severe debilitating symptoms and each urgently needing the kind of outcomes possible with vaccines based on our platform. The company’s strategic plan recognizes that limited financial, technical, and time resources need to be focused. Because the primary research which forms the foundation of the vaccine platform has been within EAE models of MS, it is multiple sclerosis in humans that will be the initial objective.
TregTherapeutics objectives, then, are clear. Resources must be assembled to proceed diligently toward a humanized version of its proprietary therapeutic tolerogenic vaccine through preclinical stages of IND enabling studies in order to initiate clinical trials. This process is proceeding. The details of that process are becoming clearer with each new day. Sourcing and formulation, manufacturing, assay development and application – these are the technical requirements for regulatory compliance and for demonstrating preliminary safety and efficacy.
Financial resources are critical to the success of the enterprise. Availability of funding has an impact on our ability to proceed with planned activities, and acquiring the resources to enable execution of the preclinical pathway is our highest priority. Non-dilutive funding is being pursued. Grant writing, along with methodically seeking out, identifying, and executing appropriate opportunities is an ongoing activity.
In addition to grant solicitation and other non-dilutive funding sources, we are also pursuing equity funding in the early stages of our development. Not content to solely rely on non-dilutive funding to move the technology forward, we have engaged in a well-organized and orchestrated effort to establish an equity partnership with either angel investors, venture capital concerns, or appropriate pharmaceutical/biotech firms. This is a key strategic element of the TregTherapeutics plan. Interested investors are urged to contact us for further information.